TH1579, MTH1 inhibitor, delays tumour growth and inhibits metastases development in osteosarcoma model

[1]  Wen-en Zhao,et al.  Potent and specific MTH1 inhibitors targeting gastric cancer , 2019, Cell Death & Disease.

[2]  Zhen Wang,et al.  Prognostic and clinicopathological significance of circulating tumor cells in osteosarcoma , 2019, Journal of bone oncology.

[3]  T. Helleday,et al.  MTH1 promotes mitotic progression to avoid oxidative DNA damage in cancer cells , 2019, bioRxiv.

[4]  I. B. Borel Rinkes,et al.  Differential anti-tumour effects of MTH1 inhibitors in patient-derived 3D colorectal cancer cultures , 2019, Scientific Reports.

[5]  G. Iliakis,et al.  The presumed MTH1-inhibitor TH588 sensitizes colorectal carcinoma cells to ionizing radiation in hypoxia , 2018, BMC Cancer.

[6]  M. Kruszewski,et al.  hMTH1 is required for maintaining migration and invasion potential of human thyroid cancer cells. , 2018, DNA repair.

[7]  M. Heymann,et al.  Isolation of circulating tumor cells in a preclinical model of osteosarcoma: Effect of chemotherapy , 2018, Journal of bone oncology.

[8]  K. Jang,et al.  The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma , 2018, Journal of Experimental & Clinical Cancer Research.

[9]  F. Gao,et al.  Anticancer effect of (S)-crizotinib on osteosarcoma cells by targeting MTH1 and activating reactive oxygen species , 2018, Anti-cancer drugs.

[10]  M. Heymann,et al.  Biology of Bone Sarcomas and New Therapeutic Developments , 2017, Calcified Tissue International.

[11]  Steven S. Foster,et al.  MTH1 deficiency selectively increases non-cytotoxic oxidative DNA damage in lung cancer cells: more bad news than good? , 2017, bioRxiv.

[12]  Haocai Chang,et al.  Induction of reactive oxygen species: an emerging approach for cancer therapy , 2017, Apoptosis.

[13]  G. Chrousos,et al.  Genome Instability and γH2AX , 2017, International journal of molecular sciences.

[14]  A. Bitto,et al.  Oxidative Stress: Harms and Benefits for Human Health , 2017, Oxidative medicine and cellular longevity.

[15]  Andreas Höglund,et al.  Glioblastoma and glioblastoma stem cells are dependent on functional MTH1 , 2017, Oncotarget.

[16]  T. Cotter,et al.  ROS signalling in the biology of cancer. , 2017, Seminars in cell & developmental biology.

[17]  Y. Nakabeppu,et al.  MTH1 as a nucleotide pool sanitizing enzyme: Friend or foe?☆ , 2017, Free radical biology & medicine.

[18]  P. Rai,et al.  MTH1 as a Chemotherapeutic Target: The Elephant in the Room , 2017, Cancers.

[19]  Y. Kallberg,et al.  Validation and development of MTH1 inhibitors for treatment of cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  Makoto Muroi,et al.  Proteomic profiling of small-molecule inhibitors reveals dispensability of MTH1 for cancer cell survival , 2016, Scientific Reports.

[21]  Graeme Walker,et al.  Potent and Selective Inhibitors of MTH1 Probe Its Role in Cancer Cell Survival. , 2016, Journal of medicinal chemistry.

[22]  T. Helleday,et al.  Addiction to MTH1 protein results in intense expression in human breast cancer tissue as measured by liquid chromatography-isotope-dilution tandem mass spectrometry. , 2015, DNA repair.

[23]  J. Lee.  Osteosarcoma in Korean children and adolescents , 2015, Korean journal of pediatrics.

[24]  Jiexiong Feng,et al.  Review of the molecular pathogenesis of osteosarcoma. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[25]  T. Helleday.  Cancer phenotypic lethality, exemplified by the non-essential MTH1 enzyme being required for cancer survival. , 2014 .

[26]  Richard Svensson,et al.  MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool , 2014, Nature.

[27]  G. Superti-Furga,et al.  Stereospecific targeting of MTH1 by (S)-crizotinib as anticancer strategy , 2014, Nature.

[28]  P. Nordlund,et al.  Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay , 2013, Science.

[29]  G. Giaever,et al.  DNA-damaging agents in cancer chemotherapy: serendipity and chemical biology. , 2013, Chemistry & biology.

[30]  R. Weinberg,et al.  Enhanced elimination of oxidized guanine nucleotides inhibits oncogenic RAS-induced DNA damage and premature senescence , 2011, Oncogene.

[31]  K. Sakumi,et al.  Programmed cell death triggered by nucleotide pool damage and its prevention by MutT homolog-1 (MTH1) with oxidized purine nucleoside triphosphatase. , 2010, Mutation research.

[32]  B. Tudek,et al.  Oxidative stress and 8-oxoguanine repair are enhanced in colon adenoma and carcinoma patients. , 2010, Mutagenesis.

[33]  P. Storz,et al.  Reactive oxygen species in cancer , 2010, Free radical research.

[34]  R. Weinberg,et al.  Continuous elimination of oxidized nucleotides is necessary to prevent rapid onset of cellular senescence , 2009, Proceedings of the National Academy of Sciences.

[35]  F. Gouin,et al.  Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies , 2007, Expert review of anticancer therapy.

[36]  F. Mseeh,et al.  Identification of potent and selective MTH1 inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[37]  P. Storz.  Reactive oxygen species in tumor progression. , 2005, Frontiers in bioscience : a journal and virtual library.

[38]  E. Rogakou,et al.  Histone H2A variants H2AX and H2AZ. , 2002, Current opinion in genetics & development.

[39]  Michael M. Murphy,et al.  ATM Phosphorylates Histone H2AX in Response to DNA Double-strand Breaks* , 2001, The Journal of Biological Chemistry.

[40]  T Ishikawa,et al.  Spontaneous tumorigenesis in mice defective in the MTH1 gene encoding 8-oxo-dGTPase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[41]  H. Kamiya,et al.  Human MTH1 protein hydrolyzes the oxidized ribonucleotide, 2-hydroxy-ATP. , 2001, Nucleic acids research.

[42]  G. Rosen,et al.  Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma , 1976, Cancer.

[43]  S. Farber,et al.  Some observations on the effect of folic acid antagonists on acute leukemia and other forms of incurable cancer. , 1949, Blood.

[44]  M. Wintrobe.  Nitrogen mustard therapy. , 1948, The American journal of medicine.

[45]  L. Goodman,et al.  NITROGEN MUSTARD THERAPY: Use of Methyl-Bis(Beta-Chloroethyl)amine Hydrochloride and Tris(Beta-Chloroethyl)amine Hydrochloride for Hodgkin's Disease, Lymphosarcoma, Leukemia and Certain Allied and Miscellaneous Disorders , 1946 .

[46]  J. Bradner,et al.  Inhibition of BET proteins and epigenetic signaling as a potential treatment for osteoporosis. , 2017, Bone.

[47]  R. Patel,et al.  Direct detection of 8-oxodeoxyguanosine and 8-oxoguanine by avidin and its analogues. , 1998, Analytical biochemistry.